



ESTRO 2026

15-19 May 2026**Stockholm, Sweden**

ESTRO 2026

AMEND

CONTINUE

Submission ID

3785

Author approval (read-only)

I confirm that this abstract has been approved by all authors.

Accuracy of the abstract (read-only)

I accept responsibility for the accuracy of the abstract. I understand that no changes to the abstract text are possible after the submission deadline of 12 November 2025 (23h59 CET).

Author list (read-only)

I confirm that all authors contributing to the abstract are properly included in the author list. I understand that no changes to the author list are possible after the 1 February 2026.

Abstract presentation (read-only)

I certify that, if the abstract is selected, the information reported is for the exclusive presentation in the scientific programme and will not be presented at any commercially-sponsored satellite symposia during the congress.

register to attend and present at the congress.

Embargo of abstracts (read-only)

I understand that abstracts are embargoed until 1 month prior to the congress at which point abstracts are published in the abstract book and online searchable programme. Should you wish for an abstract to be embargoed until the congress, please email abstracts@estro.org by 28 February 2026.

Abstract verification (read-only)

I accept to check the abstract overview provided in the submission confirmation email and ensure all abstract details are correct.

Contact person (read-only)

I accept to be the contact person for all correspondence related to the abstract and to share relevant information with the co-authors.

Topic (read-only)

Physics: Inter-fraction motion management and daily adaptive radiotherapy

Keywords (read-only)

Synthetic-CT, adaptive, thorax

Request for Digital Poster only

I want this abstract to ONLY be considered for a Digital Poster. N.B. I understand that this abstract will then NOT be considered for a live presentation (Proffered Paper, Mini-Oral, Poster Discussion).

Abstract title (read-only)

Diffusion-based synthetic-CT generation from thorax CBCT

Clinical affairs, TheraPanacea, Paris, France

Audrey Duran a.duran@therapanacea.com

AI engineering, TherePanacea, Paris, France

Quentin Spinat q.spinat@therapanacea.com

AI engineering, TheraPanacea, Paris, France

Pierre Olléon p.olleon@therapanacea.com

AI engineering, TheraPanacea, Paris, France

Olivier Teboul o.teboul@therapanacea.com

AI engineering, TheraPanacea, Paris, France

Nikolaos Paragios (Presenting) n.paragios@therapanacea.com

CEO, TheraPanacea, Paris, France

Pauline Maury pauline.maury@gustaveroussy.fr

Department of radiation oncology, Institut Gustave Roussy, Villejuif, France

Pascal Fenoglietto pascal.fenoglietto@icm.unicancer.fr

Department of radiation oncology, Institut du Cancer de Montpellier, Montpellier, France

Purpose/Objective (read-only)

Cone-beam CT (CBCT) imaging is widely used in radiotherapy for daily patient setup; however, its clinical application remains limited by suboptimal image quality, spatial resolution, and field of view. Extending CBCT beyond positioning could be key to realising the full potential of adaptive radiotherapy. Achieving this requires improved image fidelity to support accurate organ-at-risk delineation, dose calculation, and treatment replanning. This study presents and clinically evaluates an AI-driven approach to generate synthetic-CT (sCT) images from CBCT, addressing major technical limitations and demonstrating feasibility for enhancing adaptive workflows in lung cancer management.

Material/Methods (read-only)

Developing a 3D multimodal translation model for medical imaging presents challenges, including the computational burden of volumetric data, limited availability of high-quality paired datasets, and the need to preserve quantitative accuracy for clinical use. To overcome these, a 3D latent diffusion model was designed. Its variational autoencoder (VAE) component enables strong data compression while maintaining reconstruction fidelity and computational efficiency. The diffusion model was first trained in an unsupervised manner on unpaired data, then fine-tuned for cross-modality translation using limited paired samples. A ControlNet-based conditioning mechanism was implemented to ensure anatomical consistency and quantitative reliability of the generated images. The unsupervised model was trained on approximately 34000 CT scans (50% pelvis, 37.5% head and neck, 12.5% thorax) to ensure anatomical diversity, followed by fine-tuning with 286 thoracic cancer patients (2097 paired datasets).

Results (read-only)

Median relative differences in dose–volume histogram (DVH) parameters for target volumes between sCTs and wCTs were minimal (0.14–0.40% - Table 1), with the largest observed for Dmax (0.40%) and the lowest for D50% (0.14%). Median gamma pass rates reached 99.75% (2%/2 mm) and 99.94% (3%/3 mm) at a 1% low-dose threshold (Table 2), confirming excellent dosimetric agreement.

Structure	DVH parameter	Median relative difference (%)
Target volumes	Dmax [Gy]	0.40
	Dmean [Gy]	0.20
	D2% [Gy]	0.28
	D5% [Gy]	0.22
	D50% [Gy]	0.14
	D95% [Gy]	0.32
	D98% [Gy]	0.39

Gamma index	2%/2mm			3%/3mm		
Low dose threshold	1%	10%	20%	1%	10%	20%
Median	99.81	99.64	99.57	99.97	99.94	99.92

Conclusion (read-only)

This work demonstrates the feasibility and dosimetric accuracy of AI-generated sCTs from CBCT images in lung cancer radiotherapy. The results highlight the potential of this approach to improve image quality, enable accurate dose calculation, and streamline adaptive workflows for personalised and efficient treatment delivery.

Conflict of Interest Disclosure (read-only)

- ☒ I do not have a Conflict of Interest to disclose.
- ☐ I do have a Conflict of Interest to disclose.

Permission to publish (required)

In submitting this abstract, you give ESTRO permission to publish it in the congress abstract book, a supplement to the Green Journal and online in various forms (searchable programme, media library, congress platform and others).

